UC Irvine

UC Irvine Previously Published Works

Title

Melatonin, Oxidative Stress, and the Aging Brain

Permalink

<https://escholarship.org/uc/item/0t86r0wr>

ISBN

9781607616016

Authors

Bondy, Stephen
Sharman, Edward H

Publication Date

2010

DOI

10.1007/978-1-60761-602-3_17

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at

<https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

Melatonin, Oxidative Stress, and the Aging Brain

Stephen Bondy and Edward H. Sharman

Abstract The changes associated with brain aging are discussed with emphasis on altered oxidative and inflammatory events and on mitochondrial dysfunction. Many of these changes are exacerbated in a variety of age-related neurologic diseases. This commonality has led to the idea that similar therapeutic approaches may be used in the treatment of several apparently unrelated neurodegenerative disorders. When aspects of these diseases are modeled in experimental animals and cell lines, the application of melatonin has been reported to be advantageous. The means by which melatonin can be protective probably is mediated by way of activation of melatonin receptors, of which several subtypes can be identified. This can initiate a sequence of intracellular signaling events and by activation of transcription factors lead to altered gene expression. The culmination of this cascade can lead to increased levels of antioxidant enzymes and depressed levels of inflammation. Melatonin may be useful both in the retardation of nonpathologic brain aging and in the amelioration of chronic brain disease associated with aging. The inexpensive nature and ready availability of melatonin together with its very low toxicity reinforce the need to place the beneficial properties of this agent on a firmer basis.

Keywords Melatonin · Aging · Neurologic disease · Neurodegeneration · Oxidative stress · Inflammation

1 Introduction

Brain senescence involves excess free radical generation, elevated levels of basal immune and inflammatory activity, together with impaired mitochondrial function.

S. Bondy (✉)

Department of Medicine Community and Environmental Medicine, Center for Occupational and Environmental Health, University of California, Irvine, CA 92697, USA
e-mail: scbondy@uci.edu

A large number of genetic phenotypic changes occur with senescence. Some of the general changes taking place include deletions of specific portions of mitochondrial DNA [1, 2], altered immune function, and an increasingly pro-oxidant milieu concomitant with reduced antioxidant activity. Such changes have often been described as associated with brain aging [3–6]. Common neuropathologic changes include the deposition of lipofuscin and other insoluble materials such as amyloid plaques and neurofibrillary tangles. These inclusions are resistant to normal intracellular proteolytic processes and thus accumulate within and around the cell. Though such changes may characterize specific neurodegenerative disorders, they are also found with normal aging. For example, as well as being characteristic of Alzheimer's disease, amyloid plaques are present in half of the brains from an apparently normal elderly population [7]. Such indigestible inclusions consist of protein and carbohydrate components. Their accumulation is likely to disrupt cell function, in a parallel manner to the more spectacular accretion and consequent distortion of neuronal geometry seen in genetic gangliosidoses. Peptides within these complexes are cross-linked in a β -configuration, and the formation of β -sheets forms the basis for their resistance to normal ubiquitinylation and cleavage by proteases.

1.1 Oxidative Stress and Brain Aging

There are several reports suggesting that some age-related damage to the brain may be caused by excessive activity of reactive oxygen species [3, 6]. Many key intracellular constituents are vulnerable to oxidative or nitrosylative damage, and this may increase with age (reviewed in [8]). Macromolecules are especially liable to injurious oxidative modification. These include proteins [8–11], nucleic acids [12], and lipids [13]. Although an increased level of pro-oxidant activity with age has frequently been reported, the establishment of a causal relation whereby oxidant events result in impaired neurologic or behavioral status is more difficult to unequivocally demonstrate. Evidence of this nature includes the finding that treatment of aged gerbils with a free radical spin trapping agent, α -phenyl-*N*-*tert*-butyl nitron (PBN), can reverse some age-associated loss of recall ability as tested by the use of a radial arm maze [14]. In a mouse line developed for an unusually rapid onset of senescence, PBN can also diminish the degree of free radical-induced protein oxidation, and this is concomitant with improved behavioral performance [15]. Together with PBN-induced improvement of ischemic damage in stroke models using rats and marmosets, this has led to a phase 3 clinical trial for treatment of acute ischemic stroke with a derivative of PBN, disodium 4-[(*tert*-butylimino) methyl] benzene-1, 3-disulfonate *N*-oxide (NXY-059) [16].

1.2 Inflammation and the Aged Brain

The dysregulation of immune response mechanisms within the aging brain has been widely reported in recent years. Several indices of immune activity in the nervous system are persistently elevated with age despite the absence of provocative stimuli [17–20]. The microglia of the brain can act as the brain's macrophages, and

their level of activation is markedly increased in the white matter of the brains of aged rats [21] and primates [22]. The significant role of microglia in promoting adverse inflammatory processes is exemplified by the report that inhibition of microglial activation reduces the degree of damage to dopaminergic neurons caused by the selective neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [23]. However, elevated basal inflammatory activity in aged animals is not accompanied by keener immune surveillance and an improved ability to respond to an inflammatory stimulus of exogenous origin. On the contrary, the ability of the intrinsic immune system within the CNS to react to a material such as lipopolysaccharide is considerably diminished in the elderly mouse [19]. Such a dampening of the ability of immune defenses to detect relevant extraneous stimuli implies an impaired ability to mount an effective response to pathogens. Persistent levels of basal low-level inflammatory activity in the absence of exogenous stimuli is likely to be undesirable and to have deleterious consequences. The lung illustrates the injurious nature of a prolonged and futile immune response where the chronic presence of mineral particles leads to an ineffectual phagocytic attack by alveolar macrophages. This ultimately leads to severe pathologic changes involving inflammatory cytokines [24]. Analogous futile inflammatory responses in the brain may be toward aggregated amyloid peptide and other insoluble proteinaceous inclusions [25]. Thus, the elevated levels of microglial activity found in aged animals [22] may reflect a nonproductive aberrant response to endogenous factors, which cannot be resolved by raising an immune response.

1.3 Mitochondrial Dysfunction and Brain Aging

The mitochondrion is the site of the respiratory chain, and a side effect of this activity is the generation and diffusion into the cytoplasm of reactive oxidizing species; hence it also constitutes a major target of cumulative oxidative events. In fact, most of the reactive oxygen species produced within the cell have their origins from such leakage out of the respiratory chain. The electron transport is a very efficient process, but it has been estimated that around 2% of oxygen utilized escapes complete reduction to water and can form transient reactive intermediates [26]. Moreover, the efficiency of mitochondrial respiration may be further reduced with aging leading to a greater production of superoxide and other oxidant species [27–29]. After a chemical challenge, mitochondria from aged mice produce more reactive oxygen species than do mitochondria from the corresponding young mice [30]. The reduced efficiency of aged mitochondria can thus elevate levels of oxidative damage. The closest targets are most likely to be at risk, and these are structural elements of the mitochondria themselves.

It has been proposed that the increased levels of free radical generation within the aged brain are attributable to reduced efficiency of mitochondrial energy production [31, 32]. Impaired respiratory function may lead to oxidative stress and also to impairment of antioxidant enzyme systems [33]. Decline of mitochondrial functioning has also been associated with various age-related neurodegenerative

diseases including Alzheimer's, Parkinson's, and Huntington's diseases and amyotrophic lateral sclerosis [34]. Potential targets of oxidative damage to mitochondria include both their inner and outer membranes, and mitochondrial DNA (mtDNA). mtDNA is relatively exposed in comparison with nuclear DNA as it is located near the mitochondrial inner membrane and not enclosed within basic histones as is nuclear DNA. Furthermore, the mitochondrial DNA repair mechanism lacks the effectiveness and sophistication of its nuclear counterpart. Consequently, the degree of DNA damage in aging humans is 10 times greater in the mitochondria than in the nucleus [35]. In addition, the extent of mitochondrial damage is 15-fold greater in people over 70 years of age than in the younger population. This is evidenced by greater levels of gene deletions and by a much higher level of 8-hydroxy-2-deoxyguanosine in mtDNA [36]. As judged by deletion frequencies, the mutation rate of mtDNA is many fold greater in old mice relative to their young counterparts [37]. A high level of mtDNA deletions has been found to lead to reduced efficacy of mitochondrial respiration [38]. The substantia nigra is especially vulnerable to oxidative damage due to the potential of dopamine for catalytic oxidation. This may account for the selective vulnerability of dopaminergic midbrain neurons to DNA deletions in both Alzheimer's disease and Parkinson's disease [39]. Mitochondrial deletions are a driving force behind premature aging and may also have a causal role in many age-related pathologies [40]. It may be that mitochondria containing characteristic deletions, although less efficient in performing oxidative phosphorylation than normal mitochondria, are able to divide faster [41]. This raises the issue of whether such "malignant mitochondria" can gradually supplant healthy mitochondria during aging [42].

Mitochondrial dysfunction can also play an important role in the regulation of processes of cellular self-destruction, apoptosis, autophagy, and necrosis [8, 9, 43]. Control of these processes that relate to cell death is very responsive to imbalances in cellular homeostasis as gauged by such measures as Ca^{2+} levels [44] and cellular redox status [45].

2 The Treatment of Chronic Neurodegenerative Disorders

Therapeutic approaches to the most prevalent disease associated with human brain aging, Alzheimer's disease (AD), have often included anti-inflammatory regimens. These treatments have been validated by epidemiologic studies suggesting that the extended use of anti-inflammatory agents (e.g., the chronic use of aspirin by patients with arthritis) reduces the risk of AD [46]. Other epidemiologic data have suggested that antioxidants may be of value in lowering the incidence of AD [47]. Such reductions in incidence of AD attributed to anti-inflammatory or antioxidant agents could also be the result of deceleration of changes occurring during normal brain aging, rather than from effecting a direct mitigation of AD-specific changes. The search for agents with properties that target the nervous system and restore a biochemical and behavioral profile trending toward that found in younger animals may ultimately be of value in treatment of a range of distinct neurologic diseases.

The selection of appropriate materials whose prolonged usage may lead to beneficial changes within the aging central nervous system poses some distinctive problems. For example, broad, nonspecific reduction of pro-oxidant activity within the brain may disrupt those physiologic signaling events that rely on reactive oxygen species. This includes the involvement of superoxide anion in the inflammatory response. Nitric oxide (NO) is a relatively stable free radical that can combine with superoxide to form a very potent oxidant, peroxynitrite, but NO also plays an important role in the modulation of both intracellular and intercellular signals. NO has a series of key functions relating to blood supply and neurotransmission. Although protein nitrosylation is elevated with aging [22, 48], global inhibition of nitric oxide synthase aimed at protecting against neurotoxic damage [49] could have unanticipated adverse consequences, and thus such a broad-based strategy could be unsuitable. NO may be important in the prevention of cardiovascular aging by modulation of vascular tone [50].

2.1 The Potential Retardation of Brain Aging by Melatonin

The basis for selecting melatonin as an agent having the potential for slowing the onset of age-related oxidant events is based on reports from several laboratories [51–54]. A proportion of ingested melatonin can access the brain in an unmodified form [55]. On the other hand, the ability of several other potentially beneficial compounds to reach the brain is often limited due to their excessively lipophilic or water-soluble characteristics. For example, treatment of humans in one arm of the DATATOP study investigating the potential mitigation of Parkinson's disease (PD) involved α -tocopherol administration. Even after many months of such treatment, levels of this vitamin were not equilibrated within the cerebrospinal fluid, and were still rising [56]. Melatonin may be of *specific* value to the CNS where it is able to induce antioxidant genes [57]. This may account for its ability to attenuate lipopolysaccharide (LPS)-induced inflammatory responses [19, 58, 59] and to ameliorate the indices of anxiety induced by LPS [60]. β -Amyloid-induced interleukin secretion and production of reactive oxygen species are also suppressed by melatonin [61, 62]. Supercoiled mtDNA in a low entropy state in brain can be converted into more random circular and linearized forms by ethanol, and this can be attenuated by concurrent treatment with melatonin [63]. There is a considerable amount of evidence for the utility of melatonin in partially reversing changes in both the biochemical and behavioral profiles of older animals [48, 64]. Pinealectomy, which removes the major source of melatonin synthesis within the brain, may speed up changes characterizing aging [65, 66].

The use of melatonin to slow down the progression of undesirable age-related events is also supported by reports that either melatonin treatment or pineal grafting can retard the thymic involution that characterizes aging [33, 67]. It may be that aging is fundamentally an event programmed by the pineal gland [68].

The potential utility of melatonin in the deceleration of brain aging can be roughly classified into three major areas of study: (1) The application of melatonin as mitigation of overall systemic aging, including beneficial effects not confined

to the CNS such as maintenance of an effective immune function and extension of the life span. (2) The use of melatonin in the mitigation of undesirable changes associated with nonpathologic brain aging not associated with a specific neurologic disease. (3) The potential benefit of melatonin use in treatment of distinct neurologic diseases. This latter benefit has been investigated using genetic mouse lines modeling specific neurodegenerative diseases of humans.

2.1.1 Melatonin and Overall Phenotypic Aging

Extension of life span of both vertebrate and invertebrate species treated with melatonin has been described on several occasions [69–71]. This has been attributed to its ability to induce antioxidant enzymes [72] and to reduce age-related elevation of lipid peroxidation [73]. Such findings imply that melatonin has effects on the general systemic well-being rather than acting on a single organ. Such extension of longevity by melatonin has also been reported for several single-celled organisms [74]. In parallel, pinealectomy can reduce longevity [75]. This apparently beneficial effect of melatonin is further evidenced by the ability of melatonin to restore the reproductive cycle of aged mice [76] and the effective functioning of the systemic immune system of aged animals [77]. The age-related increase in susceptibility to the onset of cancer with age can be partially relieved by melatonin [75]. An inverse relation exists in several tissues, between melatonin levels and age-related oxidative damage to DNA, suggesting that this agent may exert antioxidant effects in a wide range of tissues [78].

2.1.2 Specific Effects of Melatonin on Events Relating to Brain Aging

Some of the biochemical, physiologic, and behavioral changes associated with brain aging in the absence of clinical disease include memory deficits, cerebral arterial thinning, and deposition of lipofuscin and amyloid plaques. All of these may be attenuated by chronic treatment with dietary melatonin [79–83]. Melatonin can restore the ability of the aging brain to respond to an inflammatory stimulus [19], and this is in concordance with reports of favorable effects of melatonin on the circulating immune system (described earlier). However, melatonin can also reduce excess immune responsivity (discussed in a later section). Rather than being simply pro- or anti-inflammatory, melatonin has a subtle immunoregulatory capacity.

2.1.3 The Potential for Melatonin Treatment of Specific Neurologic Disease

There are many descriptions of the potentially beneficial effect of melatonin on various neurologic and psychiatric disorders and their relevant animal models. These disorders typically become increasingly prevalent with age.

A review must judge the preponderance of current evidence and summarize the most established findings to serve as a platform for design of new studies. Considering age-related diseases with a slow rate of progression such as AD and

PD as well as aging itself, an obvious generalization is that any beneficial effects of melatonin are likely to require prolonged administration, most likely preceding the appearance of overt signs of disease. For instance, in the case of AD, a disease characterized by depressed levels of melatonin in the cerebrospinal fluid [84], preventing plaque deposition may require that exposure to exogenous melatonin be initiated in the young animal, preceding the appearance of any amyloid deposits [85].

Several reports suggest the potential effectiveness of melatonin for treating PD. Inhibition of lipid peroxidation, hydroxyl formation, and protection of nigral dopaminergic neurons in MPTP-treated rodents can be protected against by melatonin (reviewed in [86]), and exogenous melatonin has been shown to protect against L-DOPA auto-oxidation in the rat thereby increasing the availability of this drug to the striatum [87]. However, there may be a hazard in using melatonin to treat relatively acute animal models of PD involving MPTP or 6-hydroxydopamine, as the PD-like symptoms in this case may actually be worsened by melatonin application (reviewed in [88]), perhaps by inhibition of dopamine release [89].

Melatonin is also protective in preventing the oxidative damage that follows ischemia/reperfusion brain injury. This effect, which is evidenced by reduced infarct volume, necrotic neuronal death, together with diminished neurologic deficits and increased number of surviving neurons, can shield brain function [90]. The beneficial properties of melatonin in countering stroke injury can be manifested even if administered 24 h after an ischemic lesion [91].

Studies using animal models have often focused on the effect of melatonin on three major processes associated with many neurologic diseases as well as non-pathologic brain aging. This classical triad consists of (i) oxidative damage to macromolecules, (ii) persistent inflammation, and (iii) low level but prolonged hyperexcitation (excitotoxicity). All of these have been described as being mitigated by melatonin. These three classes of event, though differing, are closely interrelated and can often occur together. In consequence, it can be difficult to pinpoint the primary event that leads to a cascade of secondary changes. However, the antiexcitatory properties of melatonin are likely to be indirect changes derived from the initial antioxidant properties of melatonin [92, 93].

The problem of determining the primary initial locus of melatonin's actions and elucidating the likely chain of events that ensues is discussed next.

3 Processes That May Underlie the Ability of Melatonin to Modulate the Aging Process

3.1 Melatonin as an Antioxidant

Melatonin is present in bacteria, plants, eukaryotes, and fungi as well as all phyla of multicellular animals, and it has been suggested that its initial evolutionary role was as an antioxidant [74]. Melatonin has been reported to possess antioxidant properties

in both tissue culture and in intact animals. An unresolved issue is whether melatonin acts as an antioxidant *directly* or acts by promotion of key pathways involved in the disposition of free radicals [94]. The evidence for a direct effect rests on the fact that melatonin can act as a powerful free radical scavenger in isolated cell-free systems [95, 96]. However, it has also been reported that melatonin can act as a pro-oxidant in such systems [52, 97]. A key factor in determining this issue may be consideration of levels of free melatonin within the brain. Melatonin is present there at a concentration (around 4 pM) that is only 5% of that found in serum [55]. Therefore – unless it were to be highly concentrated in a localized area – melatonin can make little direct free-radical scavenging contribution in comparison with pre-dominant antioxidant species such as glutathione (present in millimolar amounts) and α -tocopherol (in cells at ca. 1 μ M [98]).

Melatonin is present in cerebrospinal fluid (CSF) at concentrations actually higher than serum, suggesting that the pineal may be a source of blood-borne melatonin [99]. This could account for the diurnal flux of melatonin content in both blood and cerebrospinal fluid [100]. The evidence for the involvement of activation of melatonin receptors in accounting for melatonin's antioxidant potential is described in Section 3.3.

3.2 The Role of Melatonin in the Regulation of Immune Function

Basal levels of inflammatory cytokines, their transcription factors, and glial fibrillary acidic protein (GFAP), a marker of astroglial and intrinsic immune activation, are elevated within the aging brain [46, 101, 102]. These evidences of immune activation are even more pronounced in AD [102]. Melatonin treatment reduces these age-related increases in proinflammatory activity [48, 103, 104]. The causal relation between inflammatory and oxidative events is unclear as inflammation involves oxidative activity, and free radicals can reciprocally recruit an immune response.

3.3 Melatonin Receptors and Enzyme Induction

Within the brain, there are three major plasma membrane receptors for melatonin (Table 1). Two of these, MT1 and MT2, are coupled to G-proteins whose activation leads to depression of levels of cyclic AMP. The third, MT3 or NQO2, is a quinone reductase with poorly understood *in vivo* function. However, the existence of additional melatonin binding sites in the nucleus of many cell types suggests mechanisms of action other than through plasma membrane receptors [105]. The specificity of melatonin may reside in its properties as a neurohormone, which affects transcriptional events in the CNS [57], rather than as a nonspecific antioxidant.

Table 1 Melatonin receptor subtypes and characteristics

Name	GenBank designation	UniProt designation	Other designations	Properties
Melatonin receptor type 1a	Mtnr1a	MTR1A (Q61184)	Mel1a, ML1a, ML1, MT1	353aa plasma membrane GPCR
Melatonin receptor type 1b	Mtnr1b	MTR1B (Q8CIQ6)	Mel1b, ML1b, MT2	364aa plasma membrane GPCR
NAD(P)H dehydrogenase, quinone 2; NRH:quinone oxidoreductase 2	NQO2	NQO2 (Q9JI75)	ML2, MT3	230aa zinc-binding cytoplasmic enzyme

Note: aa = amino acid

A wide range of antioxidant enzymes is induced by melatonin including glutathione peroxidase, catalase, and superoxide dismutases [106]. These protein changes are paralleled by altered levels of gene expression of oxidative enzymes [107]. In addition, levels of some pro-oxidant enzymes such as lipoxxygenase and nitric oxide synthetase are depressed after melatonin treatment [48, 108]. Several kinds of cytoplasmic melatonin receptor involve G-protein transduction and modulate transcription. MT1 activation depresses cAMP responsive-element binding protein (CREB) and stimulates extracellular-signal-regulated kinase (ERK) [109]. MT2 levels are depressed in AD [110]. Changes in these signaling pathways may form the basis of the alteration in gene expression effected by melatonin.

The interaction of melatonin with its MT3 receptor may contribute to understanding melatonin’s action at pharmacological concentrations, for, despite tight binding to MT3 ($K_i = 280\text{ nM}$), melatonin inhibits MT3 only modestly ($IC_{50} = 43\text{ }\mu\text{M}$). MT3 has been characterized as a “toxicity enzyme” [111], based on the reduced sensitivity of MT3-knockout mice to the toxic effects of the MT3 substrate menadione [112]. Thus, melatonin inhibits the (possibly toxic) activity of MT3 activity at just the concentrations where it is found to be protective pharmacologically [111].

Knockout strains of mouse lacking either MT1 or MT2 have been developed [113]. These mutants indicate that there is a limited functional redundancy between the receptor subtypes in the suprachiasmatic nucleus.

3.4 The Link Between Aging and Circadian Events

While the endogenous circadian clock seems to decline more slowly with age, the body’s ability to synchronize properly with external light cycles is diminished more rapidly [114]. There is a connection between the length of the photoperiod and aging. The mean life span of the prosimian primate *Microcebus murinus* is

decreased 28% by an accelerated photoperiodic regimen [115]. Moreover, a shortened diurnal cycle is associated with diminished nocturnal melatonin secretion [116] and can hasten the appearance of several behavioral deficits associated with aging [117]. It is interesting that the extreme longevity of healthy centenarians is associated with a pronounced diurnal flux of melatonin [118]. Light suppresses melatonin production in humans. In consideration of other evidence presented, this linkage between reduced melatonin levels and accelerated aging may be more than merely correlative. Levels of both MT1 and MT2 receptors are very high within the suprachiasmatic nucleus (SCN), the site of circadian rhythm regulation. However, levels of expression of both MT1 and MT2 mRNAs in the SCN are identical in senescence-accelerated and senescence-resistant mouse strains [119].

3.5 Melatonin and Mitochondria

There are many references documenting the ability of melatonin to maintain indices of mitochondrial health. These include downregulation of Bax, caspases, and inhibition of mitochondrial DNA fragmentation, apoptosis, cytochrome c release, and closure of the permeability transition pore. Depression of these adverse events is accompanied by induction of Bcl-2 and improved function of the respiratory chain and ATP synthesis [120–122]. Maintenance of mitochondrial glutathione levels has been also attributed to melatonin [94, 123].

Concepts concerning the possible mechanisms of melatonin's protection of mitochondrial function fall broadly into two classes; namely, direct effects of melatonin upon mitochondria and indirect effects after induction of repression of key proteins. There is little evidence of a direct effect of melatonin upon mitochondrial constituents. Direct inhibition of the mitochondrial permeability transition pore has been shown in isolated systems, but this requires micromolar concentrations of melatonin [124]. The weight of evidence suggests that mitochondrial protection is largely consequent to the induction of antioxidant enzymes and repression of apoptotic pathways. The low levels of melatonin present in tissues cannot afford much direct antioxidant power, but much amplification is provided by any action by way of gene regulation.

3.6 Summary of Mechanisms of Melatonin Action and Suggestions for Future Work

The simplest way to account for the multiplicity of effects of melatonin is to posit an early alteration of gene expression consisting of depression of mRNAs for immune-related cytokines and elevation of those for antioxidant proteins. This would lead to many of the reported enzymic changes resulting from melatonin treatment. Upstream of this may be activation of transcription factors after binding to cytoplasmic melatonin receptors or changes due to melatonin acting directly on

Fig. 1 Potential relationships between regulated melatonin levels and their consequent effect on brain aging

nuclear receptors. Melatonin receptors are not well characterized, and no specific antagonists are available. Thus, circulating melatonin levels, which fluctuate under circadian influence but which are depressed with age, could dynamically influence levels of oxidative and inflammatory activity (Fig. 1). Further research in characterizing melatonin receptors could lead to better delineation of the sequence of events by which melatonin exerts its effects.

4 Conclusions

The median age of the U.S. population is rapidly increasing, and this will lead to a corresponding increase in the incidence of many age-related syndromes. Aging is often associated with both memory and motor deficits including impaired locomotor, postural, and balancing skills. The potential for major increases in incidence of neurodegenerative disorders will be especially pronounced in view of the declining cardiovascular death rate. Retardation of the appearance of changes found with non-pathologic aging could postpone the clinical onset of diseases such as Parkinsonism and Alzheimer's disease. It may be that one of the most rewarding approaches to mitigation of the societal effects of these diseases lies in the deceleration of changes associated with normal cerebral senescence that are not specifically associated with any neurologic disease. Although the onset of neurologic disease generally does not represent merely an acceleration of normal aging, it is obviously based on a platform

of aging. Both normal aging and pathologic processes in part involve changes in the same loci. The identification and protection of such common targets can be valuable in the development of strategies designed to delay the manifestation of common neurodegenerative disorders. The slow progression over a substantial portion of an individual's adult life span with these conditions suggests that, to be effective, treatments such as dietary supplementation need to be followed over many years. This lengthy treatment of essentially "well" patients requires that both the effectiveness and safety of such regimens be rigorously investigated – initially in animal models – before their widespread use can be confidently advocated.

As only 9% of Americans eat the recommended five servings of fruits and vegetables daily [4], the opportunity for retarding neural aging by modifying the intake of exogenous nutrients is high. Dietary supplementation as a means of delaying age-related neural disorders is more likely to be adhered to than any regimen based on caloric restriction, which is known to retard aging processes. However, no dietary supplement has yet been found as effective as caloric restriction in extending life span [125]. The consumption of melatonin on a regular basis may help to mitigate some aspects of brain aging and appears to pose very little downside risk. Any potential benefits will occur over a long time and will thus be hard to definitively document in humans. Data derived from animal studies suggest the value of melatonin. Aging is a multifactorial process, and the advocacy of a single remedial agent is clearly incomplete. Unlike the focused pharmacological remediation for a specific disorder, amelioration of the wider range of changes associated with normal aging is obviously best addressed with a multiplicity of nutritional and physiologic modifications. However, melatonin has utility as a means of retarding some aspects of brain aging. In addition to the experimental evidence described above, melatonin has several positive features that enhance its candidacy as a therapeutic agent. Melatonin is an evolutionarily ancient neurohormone that has very low toxicity and no carcinogenic properties, and this makes it a very safe compound. It is also readily available and has a low cost. Melatonin is likely to constitute an inexpensive and nonhazardous means of maintaining the functionality of the aging brain.

Acknowledgments This work was supported in part by a grant from the National Institutes of Health (AG 16794) and by a UC Davis Center for Human and Nutrition Pilot Award (CHNR08-318).

References

1. Melov S, Schneider JA, Coskun PE, Bennett DA, Wallace DC. Mitochondrial DNA rearrangements in aging human brain and in situ PCR of mtDNA. *Neurobiol Aging*. 1999;20:565–571.
2. Wei YH, Lee HC. Oxidative stress, mitochondrial DNA mutation, and impairment of antioxidant enzymes in aging. *Exp Biol Med*. 2002;227:671–682.
3. LeBel CP, Bondy SC. Oxidative damage and cerebral aging. *Prog Neurobiol*. 1992;38:601–609.
4. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. *Proc Natl Acad Sci USA*. 1993;90:7915–7922.

5. Lass A, Sohal BH, Weindruch R, Forster MJ, Sohal RS. Caloric restriction prevents age-associated accrual of oxidative damage to mouse skeletal muscle mitochondria. *Free Radic Biol Med.* 1998;25:1089–1097.
6. Calabrese V, Bates TE, Stella AM. NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant/antioxidant balance. *Neurochem Res.* 2000;25:1315–1341.
7. Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. *Neurobiol Aging.* 1991;12:295–312.
8. Kim R, Emi M, Tanabe K. Role of mitochondria as the gardens of cell death. *Cancer Chemother Pharmacol.* 2006;57:545–553.
9. Poon HF, Calabrese V, Scapagnini G, Butterfield DA. Free radicals and brain aging. *Clin Geriatr Med.* 2004;20:329–359.
10. Davies MJ. The oxidative environment and protein damage. *Biochim Biophys Acta.* 2005;1703:93–109.
11. Sohal RS, Agarwal S, Dubey A, Orr WC. Protein oxidative damage is associated with life expectancy of houseflies. *Proc Natl Acad Sci USA.* 1993;90:7255–7259.
12. Fraga CG, Shigenaga MK, Park JW, Degan P, Ames BN. Oxidative damage to DNA during aging: 8-hydroxy-2'-deoxyguanosine in rat organ DNA and urine. *Proc Natl Acad Sci USA.* 1990;87:4533–4537.
13. Roberts LJ II, Reckelhoff JF. Measurement of F2-isoprostanes unveils profound oxidative stress in aged rats. *Biochem Biophys Res Commun.* 2001;287:254–256.
14. Sack CA, Socci DJ, Crandall BM, Arendash GW. Antioxidant treatment with phenyl-alpha-tert-butyl nitron (PBN) improves the cognitive performance and survival of aging rats. *Neurosci Lett.* 1996;205:181–184.
15. Butterfield DA, Martin L, Carney JM, Hensley K. A beta (25-35) peptide displays H2O2-like reactivity towards aqueous Fe2+, nitroxide spin probes, and synaptosomal membrane proteins. *Life Sci.* 1996;58:217–228.
16. Floyd RA. Nitrones as therapeutics in age-related diseases. *Aging Cell.* 2006;1:51–57.
17. Terrazzino S, Perego C, De Luigi A, De Simoni MG. Interleukin-6, tumor necrosis factor and corticosterone induction by central lipopolysaccharide in aged rats. *Life Sci.* 1997;61:695–701.
18. Xie Z, Morgan TE, Rozovsky I, Finch CE. Aging and glial responses to lipopolysaccharide in vitro: greater induction of IL-1 and IL-6, but smaller induction of neurotoxicity. *Exp Neurol.* 2003;182:135–141.
19. Sharman KG, Sharman E, Bondy SC. Dietary melatonin selectively reverses age-related changes in cortical basal cytokine mRNA levels, and their responses to an inflammatory stimulus. *Neurobiol Aging.* 2002;23:633–638.
20. Sharman E, Sharman KG, Lahiri DK, Bondy SC. Age-related changes in murine CNS mRNA gene expression are modulated by dietary melatonin. *J Pineal Res.* 2004;36:165–170.
21. Perry VH, Matyszak MK, Fearn S. Altered antigen expression of microglia in the aged rodent CNS. *Glia.* 1993;7:60–67.
22. Sloane JA, Hollander W, Moss MB, Rosene DL, Abraham CR. Increased microglial activation and protein nitration in white matter of the aging monkey. *Neurobiol Aging.* 1999;20:395–405.
23. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. *J Neurosci.* 2002;22:1763–1771.
24. Rimal B, Greenberg AK, Rom WN. Basic pathogenetic mechanisms in silicosis: current understanding. *Curr Opin Pulm Med.* 2005;11:169–173.

25. Bondy SC, Campbell A. Initiation of futile pathways common to many neurological diseases. In: Marwah J, Lo E (eds.), *Neuroprotection*. Prominent Press, Scottsdale, 2002, pp. 299–309.
26. Boveris A, Chance B. The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. *Biochem J*. 1973;134:707–716.
27. Harman D. Alzheimer's disease: role of aging in pathogenesis. *Ann NY Acad Sci*. 2002;959:384–395.
28. Kokoszka JE, Coskun P, Esposito LA, Wallace DC. Increased mitochondrial oxidative stress in the Sod2 (+/-) mouse results in the age-related decline of mitochondrial function culminating in increased apoptosis. *Proc Natl Acad Sci USA*. 2001;98:2278–2283.
29. Sasaki T, Unno K, Tahara S, Shimada A, Chiba Y, Hoshino M, Kaneko T. Age-related increase of superoxide generation in the brains of mammals and birds. *Aging Cell*. 2008;7:459–469.
30. Liu J, Ames BN. Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease. *Nutr Neurosci*. 2005;8:67–89.
31. Ames BN, Atamna H, Killilea DW. Mineral and vitamin deficiencies can accelerate the mitochondrial decay of aging. *Mol Aspects Med*. 2005;26:363–378.
32. Cocco T, Sgobbo P, Clemente M, Lopriore B, Grattagliano I, Di Paola M, Villani G. Tissue-specific changes of mitochondrial functions in aged rats: effect of a long-term dietary treatment with N-acetylcysteine. *Free Radic Biol Med*. 2005;38:796–805.
33. Tian L, Cai Q, Wei H. Alterations of antioxidant enzymes and oxidative damage to macromolecules in different organs of rats during aging. *Free Radic Biol Med*. 1998;24:1477–1484.
34. Bowling AC, Beal MF. Bioenergetic and oxidative stress in neurodegenerative diseases. *Life Sci*. 1995;56:1151–1171.
35. Mecocci P, MacGarvey U, Kaufman AE, Koontz D, Shoffner JM, Wallace DC, Beal MF. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. *Ann Neurol*. 1993;34:609–616.
36. Mecocci P, Beal MF, Cecchetti R, Polidori MC, Cherubini A, Chionne F, Avellini L, Romano G, Senin U. Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. *Mol Chem Neuropathol*. 1997;31:53–64.
37. Wang E, Wong A, Cortopassi G. The rate of mitochondrial mutagenesis is faster in mice than humans. *Mutat Res*. 1997;377:157–166.
38. Sobreira C, Davidson M, King MP, Miranda AF. Dihydrorhodamine 123 identifies impaired mitochondrial respiratory chain function in cultured cells harboring mitochondrial DNA mutations. *J Histochem Cytochem*. 1996;44:571–579.
39. Bender A, Schwarzkopf RM, McMillan A, Krishnan KJ, Rieder G, Neumann M, Elstner M, Turnbull DM, Klopstock T. Dopaminergic midbrain neurons are the prime target for mitochondrial DNA deletions. *J Neurol*. 2008;255:1231–1235.
40. Vermulst M, Wanagat J, Kujoth GC, Bielas JH, Rabinovitch PS, Prolla TA, Loeb LA. DNA deletions and clonal mutations drive premature aging in mitochondrial mutator mice. *Nat Genet*. 2008;40:392–394.
41. Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, McKee AC, Beal MF, Graham BH, Wallace DC. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. *Genomics*. 1994;23:471–476.
42. Fukui H, Moraes CT. Mechanisms of formation and accumulation of mitochondrial DNA deletions in aging neurons. *Hum Mol Genet*. 2009;18:1028–1036.
43. Skulachev VP. Bioenergetic aspects of apoptosis, necrosis and mitoptosis. *Apoptosis*. 2006;11:473–485.
44. Halestrap AP. Calcium, mitochondria and reperfusion injury: a pore way to die. *Biochem Soc Trans*. 2006;34:232–237.

45. Haddad JJ. Redox and oxidant-mediated regulation of apoptosis signaling pathways: immuno-pharmaco-redox conception of oxidative siege versus cell death commitment. *Int Immunopharmacol.* 2004;4:475–493.
46. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. *Neurobiol Aging.* 2007;28:639–647.
47. Pitchumoni SS, Doraiswamy PM. Current status of antioxidant therapy for Alzheimer's disease. *J Am Geriatr Soc.* 1998;46:1566–1572.
48. Sharman EH, Vaziri ND, Ni Z, Sharman KG, Bondy SC. Reversal of biochemical and behavioral parameters of brain aging by melatonin and acetyl L-carnitine. *Brain Res.* 2002;95:223–230.
49. Itzhak Y, Ali SF. The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo. *J Neurochem.* 1996;67:1770–1773.
50. Santhanam L, Christianson DW, Nyhan D, Berkowitz DE. Arginase and vascular aging. *J Appl Physiol.* 2008;105:1632–1642.
51. Cuzzocrea S, Costantino G, Gitto E, Mazzon E, Fulia F, Serraino I, Cordaro S, Barberi I, De Sarro A, Caputi AP. Protective effects of melatonin in ischemic brain injury. *J Pineal Res.* 2000;29:217–227.
52. Bondy SC, Yang YE, Walsh TJ, Gie YW, Lahiri DK. Dietary modulation of age-related changes in cerebral pro-oxidant status. *Neurochem Int.* 2002;40:123–130.
53. Bondy SC, Sharman EH. Melatonin and the aging brain. *Neurochem Int.* 2007;50:571–580.
54. Korkmaz A, Reiter RJ, Topal T, Manchester LC, Oter S, Tan DX. Melatonin: an established antioxidant worthy of use in clinical trials. *Mol Med.* 2009;15:43–50.
55. Lahiri DK, Ge YW, Sharman EH, Bondy SC. Age-related changes in serum melatonin in mice: higher levels of combined melatonin and 6-hydroxymelatonin sulfate in the cerebral cortex than serum, heart, liver and kidney tissues. *J Pineal Res.* 2004;36:217–223.
56. Vatsary GT, Fahn S, Kuskowski MA. Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson Study Group. *Neurology.* 1998;50:1900–1902.
57. Kotler M, Rodriguez C, Sainz RM, Antolin I, Menendez-Pelaez A. Melatonin increases gene expression for antioxidant enzymes in rat brain cortex. *J Pineal Res.* 1998;24:83–89.
58. Sewerynek E, Abe M, Reiter RJ, Barlow-Walden LR, Chen L, McCabe TJ, Roman LJ, Diaz-Lopez B. Melatonin administration prevents lipopolysaccharide-induced oxidative damage in phenobarbital-treated animals. *J Cell Biochem.* 1995;58:436–444.
59. Lezoualch F, Sparapani M, Behl C. N-acetyl-serotonin (normelatonin) and melatonin protect neurons against oxidative challenges and suppress the activity of the transcription factor NF-kappaB. *J Pineal Res.* 1998;24:168–178.
60. Nava F, Carta G. Melatonin reduces anxiety induced by lipopolysaccharide in the rat. *Neurosci Lett.* 2001;307:57–60.
61. Clapp-Lilly KL, Smith MA, Perry G, Duffy LK. Melatonin reduces interleukin secretion in amyloid-beta stressed mouse brain slices. *Chem Biol Interact.* 2001;134:101–107.
62. Masilamoni JG, Jesudason EP, Dhandayuthapani S, Ashok BS, Vignesh S, Jebaraj WC, Paul SF, Jayakumar R. The neuroprotective role of melatonin against amyloid beta peptide injected mice. *Free Radic Res.* 2008;42:661–673.
63. Mansouri A, Demeilliers C, Amsellem S, Pessayre D, Fromenty B. Acute ethanol administration oxidatively damages and depletes mitochondrial DNA in mouse liver, brain, heart, and skeletal muscles: protective effects of antioxidants. *J Pharmacol Exp Ther.* 2001;298:737–743.
64. Reiter RJ, Tan DX, Manchester LC, Tamura H. Melatonin defeats neurally-derived free radicals and reduces the associated neuromorphological and neurobehavioral damage. *J Physiol Pharmacol.* 2007;58(Suppl 6):5–22.

65. Reiter RJ, Tan D, Kim SJ, Manchester LC, Qi W, Garcia JJ, Cabrera JC, El-Sokkary G, Rouvier-Garay V. Augmentation of indices of oxidative damage in life-long melatonin-deficient rats. *Mech Ageing Dev.* 1999;110:157–173.
66. Payao SL, de Carvalho CV, da Silva ER, Lopes C, Markus RP, Winter LM, Smith MA. Pinealectomy-associated decrease in ribosomal gene activity in rats. *Biogerontology.* 2001;2:105–108.
67. Provinciali M, Di Stefano G, Bulian D, Tibaldi A, Fabris N. Effect of melatonin and pineal grafting on thymocyte apoptosis in aging mice. *Mech Ageing Dev.* 1996;90:1–19.
68. Pierpaoli W. Neuroimmunomodulation of aging. A program in the pineal gland. *Ann NY Acad Sci.* 1998;840:491–497.
69. Oaknin-Bendahan S, Anis Y, Nir I, Zisapel N. Effects of long-term administration of melatonin and a putative antagonist on the ageing rat. *Neuroreport.* 1995;6:785–788.
70. Bonilla E, Medina-Leendertz S, Diaz S. Extension of life span and stress resistance of *Drosophila melanogaster* by long-term supplementation with melatonin. *Exp Gerontol.* 2002;37:629–638.
71. Anisimov SV, Popovic N. Genetic aspects of melatonin biology. *Rev Neurosci.* 2004;15:209–230.
72. Caballero B, Vega-Naredo I, Sierra V, Huidobro-Fernández C, Soria-Valles C, De Gonzalo-Calvo D, Tolivia D, Pallás M, Camins A, Rodríguez-Colunga MJ, Coto-Montes A. Melatonin alters cell death processes in response to age-related oxidative stress in the brain of senescence-accelerated mice. *J Pineal Res.* 2009;46:106–114.
73. Akbulut KG, Gonül B, Akbulut H. Exogenous melatonin decreases age-induced lipid peroxidation in the brain. *Brain Res.* 2008;1238:31–35.
74. Hardeland R, Poeggeler B. Non-vertebrate melatonin. *J Pineal Res.* 2003;34:233–234.
75. Bulian D, Pierpaoli W. The pineal gland and cancer. I. Pinealectomy corrects congenital hormonal dysfunctions and prolongs life of cancer-prone C3H/He mice. *J Neuroimmunol.* 2000;108:131–135.
76. Diaz E, Pazo D, Esquifino AI, Diaz B. Effects of ageing and exogenous melatonin on pituitary responsiveness to GnRH in rats. *J Reprod Fertil.* 2000;119:151–156.
77. Akbulut KG, Gonul B, Akbulut H. The effects of melatonin on humoral immune responses of young and aged rats. *Immunol Invest.* 2001;30:17–20.
78. Morioka N, Okatani Y, Wakatsuki A. Melatonin protects against age-related DNA damage in the brains of female senescence-accelerated mice. *J Pineal Res.* 1999;27:202–209.
79. Matsubara E, Bryant-Thomas T, Pacheco Quinto J, Henry TL, Poeggeler B, Herbert D, Cruz-Sanchez F, Chyan YJ, Smith MA, Perry G, Shoji M, Abe K, Leone A, Grundke-Ikbal I, Wilson GL, Ghiso J, Williams C, Refolo LM, Pappolla MA, Chain DG, Neria E. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. *J Neurochem.* 2003;85:1101–1108.
80. Bondy SC, Lahiri DK, Perreau VM, Sharman KZ, Campbell A, Zhou J, Sharman EH. Retardation of brain aging by chronic treatment with melatonin. *Ann NY Acad Sci.* 2004;1035:197–215.
81. Dupuis F, Regrigny O, Atkinson J, Liminana P, Delagrangé P, Scalbert E, Chillon JM. Impact of treatment with melatonin on cerebral circulation in old rats. *Br J Pharmacol.* 2004;141:399–406.
82. Lahiri DK, Chen DM, Lahiri P, Bondy S, Greig NH. Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases. *Ann NY Acad Sci.* 2005;1056:430–449.
83. Abd El Mohsen MM, Irvani MM, Spencer JP, Rose S, Fahim AT, Motawi TM, Ismail NA, Jenner P. Age-associated changes in protein oxidation and proteasome activities in rat brain: modulation by antioxidants. *Biochem Biophys Res Commun.* 2005;36:386–391.
84. Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. *J Pineal Res.* 2003;35:125–130.

85. Quinn J, Kulhanek D, Nowlin J, Jones R, Pratico D, Rokach J, Stackman R. Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. *Brain Res.* 2005;1037:209–213.
86. Mayo JC, Sainz RM, Tan DX, Antolin I, Rodriguez C, Reiter RJ. Melatonin and Parkinson's disease. *Endocrine.* 2005;27:169–178.
87. Rocchitta G, Migheli R, Esposito G, Marchetti B, Desole MS, Miele E, Serra PA. Endogenous melatonin protects L-DOPA from autoxidation in the striatal extracellular compartment of the freely moving rat: potential implication for long-term L-DOPA therapy in Parkinson's disease. *J Pineal Res.* 2006;40:204–213.
88. Willis GL. The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson's disease. *Drug News Perspect.* 2005;18:437–444.
89. Zisapel N. Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. *Cell Mol Neurobiol.* 2001;21:605–616.
90. Cervantes M, Morali G, Letechipía-Vallejo G. Melatonin and ischemia-reperfusion injury of the brain. *J Pineal Res.* 2008;45:1–7.
91. Kilic E, Kilic U, Bacigaluppi M, Guo Z, Abdallah NB, Wolfer DP, Reiter RJ, Hermann DM, Bassetti CL. Delayed melatonin administration promotes neuronal survival, neurogenesis and motor recovery, and attenuates hyperactivity and anxiety after mild focal cerebral ischemia in mice. *J Pineal Res.* 2008;45:142–148.
92. Skaper SD, Floreani M, Ceccon M, Facci L, Giusti P. Excitotoxicity, oxidative stress, and the neuroprotective potential of melatonin. *Ann NY Acad Sci.* 1999;890:107–118.
93. Cheung RT. The utility of melatonin in reducing cerebral damage resulting from ischemia and reperfusion. *J Pineal Res.* 2003;34:153–160.
94. Sheth DS, Tajuddin NF, Druse MJ. Antioxidant neuroprotection against ethanol-induced apoptosis in HN2-5 cells. *Brain Res.* 2009;1285:14–21.
95. Beyer CE, Steketee JD, Saphier D. Antioxidant properties of melatonin – an emerging mystery. *Biochem Pharmacol.* 1998;56:1265–1272.
96. Tan DX, Reiter RJ, Manchester LC, Yan MT, El-Sawi M, Sainz RM, Mayo JC, Kohen R, Allegra M, Hardeland R. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. *Curr Top Med Chem.* 2002;2:181–197.
97. Buyukavci M, Ozdemir O, Buck S, Stout M, Ravindranath Y, Savasan S. Melatonin cytotoxicity in human leukemia cells: relation with its pro-oxidant effect. *Fundam Clin Pharmacol.* 2006;20:73–79.
98. Sebastià J, Cristòfol R, Martín M, Rodríguez-Farré E, Sanfeliu C. Evaluation of fluorescent dyes for measuring intracellular glutathione content in primary cultures of human neurons and neuroblastoma SH-SY5Y. *Cytometry Part A.* 2003;51A:16–25.
99. Rousseau A, Petren S, Planthoin J, Eklundh T, Nordin C. Serum and cerebrospinal fluid concentrations of melatonin: a pilot study in healthy male volunteers. *J Neural Transm.* 1999;106:883–888.
100. Debus OM, Lerchl A, Bothe HW, Bremer J, Fiedler B, Franssen M, Koehring J, Steils M, Kurlemann G. Spontaneous central melatonin secretion and resorption kinetics of exogenous melatonin: a ventricular CSF study. *J Pineal Res.* 2002;33:213–217.
101. Yu WH, Go L, Guinn BA, Fraser PE, Westaway D, McLaurin J. Phenotypic and functional changes in glial cells as a function of age. *Neurobiol Aging.* 2002;23:105–115.
102. Griffin WS. Inflammation and neurodegenerative diseases. *Am J Clin Nutr.* 2006;83:470S–474S.
103. Baydas G, Reiter RJ, Nedzvetskii VS, Nerush PA, Kirichenko SV. Altered glial fibrillary acidic protein content and its degradation in the hippocampus, cortex and cerebellum of rats exposed to constant light: reversal by melatonin. *J Pineal Res.* 2002;33:134–139.
104. Gunasingh MJ, Philip JE, Ashok BS, Kirubakaran R, Jebaraj WC, Davis GD, Vignesh S, Dhandayuthapani S, Jayakumar R. Melatonin prevents amyloid protofibrillar induced oxidative imbalance and biogenic amine catabolism. *Life Sci.* 2008;18(83):96–102.

105. Filadelfi AM, Castrucci AM. Comparative aspects of the pineal/melatonin system of poikilothermic vertebrates. *J Pineal Res.* 1996;20:175–186.
106. Manda K, Bhatia AL. Melatonin-induced reduction in age-related accumulation of oxidative damage in mice. *Biogerontology.* 2003;4:133–139.
107. Anisimov VN, Popovich IG, Zabezhinskii MA, Rozenfel'd SV, Khavinson VKH, Semenchenko AV, Iashin AI. Effect of epitalon and melatonin on life span and spontaneous carcinogenesis in senescence accelerated mice (SAM). *Vopr Onkol.* 2005;51: 93–98.
108. Reiter RJ, Acuna-Castroviejo D, Tan DX, Burkhardt S. Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. *Ann NY Acad Sci.* 2001;939:200–215.
109. Chan AS, Lai FP, Lo RK, Voyno-Yasenetskaya TA, Stanbridge EJ, Wong YH. Melatonin MT1 and MT2 receptors stimulate c-Jun N-terminal kinase via pertussis toxin-sensitive and -insensitive G proteins. *Cell Signal.* 2002;14:249–257.
110. Savaskan E, Ayoub MA, Ravid R, Angeloni D, Fraschini F, Meier F, Eckert A, Muller-Spahn F, Jockers R. Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease. *J Pineal Res.* 2005;38:10–16.
111. Mailliet F, Ferry G, Vella F, Thiam K, Delagrang P, Boutin JA. Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding site MT3. *FEBS Lett.* 2004;578:116–120.
112. Long DJ, Iskander K, Gaikwad A, Arin M, Roop DR, Knox R, Barrios R, Jaiswal AK. Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. *J Biol Chem.* 2002;277:46131–46139.
113. Jin X, von Gall C, Pieschl RL, Gribkoff VK, Stehle JH, Reppert SM, Weaver DR. Targeted disruption of the mouse Mel(1b) melatonin receptor. *Mol Cell Biol.* 2003;23:1054–1060.
114. Weinert D. Age-dependent changes of the circadian system. *Chronobiol Int.* 2000;17: 261–283.
115. Perret M. Change in photoperiodic cycle affects life span in a prosimian primate (*Microcebus murinus*). *J Biol Rhythms.* 1997;12:136–145.
116. Aujard F, Dkhissi-Benyahya O, Fournier I, Claustrat B, Schilling A, Cooper HM, Perret M. Artificially accelerated aging by shortened photoperiod alters early gene expression (Fos) in the suprachiasmatic nucleus and sulfatoxymelatonin excretion in a small primate, *Microcebus murinus*. *Neuroscience.* 2001;105:403–412.
117. Cayetanot F, Van Someren EJ, Perret M, Aujard F. Shortened seasonal photoperiodic cycles accelerate aging of the diurnal and circadian locomotor activity rhythms in a primate. *J Biol Rhythms.* 2005;20:461–469.
118. Ferrari E, Cravello L, Falvo F, Barili L, Solerte SB, Fioravanti M, Magri F. Centenarians have good diurnal flux of melatonin: neuroendocrine features in extreme longevity. *Exp Gerontol.* 2008;43:88–94.
119. Asai M, Ikeda M, Akiyama M, Oshima I, Shibata S. Administration of melatonin in drinking water promotes the phase advance of light-dark cycle in senescence-accelerated mice, SAMR1 but not SAMP8. *Brain Res.* 2000;876:220–224.
120. Yoo YM, Yim SV, Kim SS, Jang HY, Lea HZ, Hwang GC, Kim JW, Kim SA, Lee HJ, Kim CJ, Chung JH, Leem KH. Melatonin suppresses NO-induced apoptosis via induction of Bcl-2 expression in PGT-beta immortalized pineal cells. *J Pineal Res.* 2002;33: 146–150.
121. Feng Z, Qin C, Chang Y, Zhang JT. Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. *Free Radic Biol Med.* 2006;40:101–109.
122. Yon JH, Carter LB, Reiter RJ, Jevtovic-Todorovic V. Melatonin reduces the severity of anesthesia-induced apoptotic neurodegeneration in the developing rat brain. *Neurobiol Dis.* 2006;21:522–530.

123. Leon J, Acuna-Castroviejo D, Escames G, Tan DX, Reiter RJ. Melatonin mitigates mitochondrial malfunction. *J Pineal Res.* 2005;38:1–9.
124. Andrabi SA, Sayeed I, Siemen D, Wolf G, Horn TF. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. *FASEB J.* 2004;18:869–871.
125. Lee CK, Pugh TD, Klopp RG, Edwards J, Allison DB, Weindruch R, Prolla TA. The impact of alpha-lipoic acid, coenzyme Q10 and caloric restriction on life span and gene expression patterns in mice. *Free Radic Biol Med.* 2004;36:1043–1057.